After a 7-year odyssey at the FDA, Merck finally wins an OK for Bridion

John Carroll

For the past 7 years has maintained a star rating by its program for (sugammadex), remaining convinced of its big market potential and staying upbeat three consecutive rejections at the hands of the FDA. But regulators relented today, giving the pharma giant a green light on its fourth try for the drug, which is used to reverse the effects of adult anesthetics.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS